Vanguard Capital Management
ALGS icon

Vanguard Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Vanguard Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
175,543
-2,719
-2% -$16.8K ﹤0.01% 3594
2026
Q1 		$1.32M Buy
+178,262
New +$1.35M ﹤0.01% 3488

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management's ALGS Position: Q2 2026 in Review

Vanguard Capital Management reduced its Aligos Therapeutics (ALGS) stake by 1.5% in Q2 2026, selling an estimated $16.8K and leaving 175,543 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3594.

Vanguard Capital Management first reported a position in ALGS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.32M in Q1 2026. 29 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Vanguard Capital Management held 175,543 shares of Aligos Therapeutics worth $1.01M as of Q2 2026.
  • Vanguard Capital Management sold 2,719 Aligos Therapeutics shares in Q2 2026, an estimated $16.8K.
  • Aligos Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3594 holding.
  • Vanguard Capital Management first reported a position in Aligos Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Aligos Therapeutics position peaked at $1.32M in Q1 2026.
  • 29 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.